Bluebird Bio has pushed forward the conversation on how to make million-dollar treatments affordable for insurers, but biopharma and payers are ominously quiet about…
The FDA has made a lot of noise about its plans to make medical devices safer. But these plans are somewhat amorphous; any meaningful steps would likely require…
The industry has its work cut out to rebuild trust in the tech following doubts about one pioneer, IBM Watson.
Drug discovery is getting harder, and some companies are turning to machine learning to look for new targets.
Big pharma is using machine learning to improve the drug development process – but can the tech live up to the hype?
As drug prices climb, is it time to ask whether the landmark technology transfer law is a fair deal for US taxpayers?
The high doses of recently studied gene therapies threaten manufacturing problems that few have fully considered.
Roche's Hemlibra has impressed, but uptake might not be as fast as some hope.
Growing acceptance of medical marijuana could see cannabis companies coming after pharma sales.